The analysis brought together patients followed at four major centers: the Brazilian National Cancer Institute in Rio de Janeiro, the Hospital das Clínicas of the Universidade Federal de Minas Gerais in Belo Horizonte, the University of Alberta in Edmonton and the Fondazione IRCCS Policlinico San Matteo in Pavia, Italy. Participants had been enrolled in one observational study and three interventional trials, all prospectively registered, and each contributed baseline measurements together with at least twelve months of survival follow-up. The pooled cohort was 59.1 percent male, with a mean age of 61.2 years, and was dominated by gastrointestinal cancer, which accounted for roughly three-quarters of cases; nearly half of the patients had stage IV disease. Over a median follow-up of 43 months, 188 patients, or 39.4 percent of the cohort, died, giving the investigators enough events to test every muscle-related marker rigorously in multivariable models while adjusting for age, sex, performance status, disease stage and treatment setting.

The question the researchers posed reflects a quiet tension running through modern nutritional oncology. Reduced skeletal muscle mass and reduced muscle radiodensity, the brightness of muscle on a CT scan, which falls as fat infiltrates the tissue, have each been linked in previous work to shorter survival, poorer quality of life and heightened chemotherapy toxicity. As a result, guidelines increasingly encourage clinicians to evaluate body composition in every patient at nutritional risk. Yet international sarcopenia frameworks have simultaneously shifted their emphasis: in chronic disease, both muscle mass and muscle strength should be assessed, but strength is now considered the primary criterion. Studies in cancer populations have hinted that impaired muscle function portends worse outcomes, including mortality, dose-limiting chemotherapy toxicity and perioperative complications, even in patients whose lean mass appears preserved, and that risk climbs further when weakness and atrophy coexist. What remained unclear was which marker deserves priority when the two disagree, precisely the situation clinicians confront daily.

To resolve that question, the team standardized four exposures across the three countries. Muscle mass was quantified from CT images acquired within sixty days before assessment at the level of the third lumbar vertebra, the accepted surrogate for whole-body skeletal muscle. Using Slice-O-Matic software and attenuation thresholds of −29 to 150 Hounsfield units, analysts outlined the skeletal muscle area encompassing the psoas, erector spinae, quadratus lumborum, transversus abdominis, internal and external obliques and rectus abdominis, then divided it by height squared to obtain the skeletal muscle index. Muscle composition was captured as radiodensity in Hounsfield units, a proxy for fat infiltration, and patients were classed as high risk if they fell in the lowest sex- and country-specific quartile of either measure. Strength was assessed by digital or hydraulic hand dynamometry in the dominant hand, with three standardized trials in a sitting posture, elbow flexed at ninety degrees, and the largest value retained. Low strength was defined against population references, such as 27 kilograms for men and 16 for women of European ancestry, or 29.7 and 16.2 kilograms for Brazilian norms. Unintentional weight loss over the previous six months was flagged at the conventional threshold of ten percent of usual body weight.

The prevalence figures alone reveal how differently these markers behave. Low skeletal muscle index affected 24.7 percent of patients and low muscle density 24.9 percent, yet low handgrip strength was present in 31.7 percent and clinically relevant weight loss in 32.3 percent. The three countries painted distinct profiles: Canadian patients carried the largest muscle reserves and the strongest grips, Italian participants were the leanest and weakest with the greatest weight losses, and Brazilian patients showed the lowest muscle radiodensity despite respectable strength. Kaplan–Meier survival curves then delivered the study’s first surprise. All the paired strata, low grip strength combined with low muscle index, low grip strength with low density, and low grip strength with weight loss, were statistically associated with mortality. But looking within each pairing produced a consistent pattern: neither low muscle index nor low muscle density meaningfully separated survival curves, whether handgrip strength was normal or reduced. Only weight loss of ten percent or more consistently split patients into clearly different prognostic groups, independent of how hard they could squeeze a dynamometer.

Fully adjusted Cox regression models, controlling for age, sex, performance status, disease stage and treatment setting, sharpened the message. In the model entering all four markers simultaneously, low skeletal muscle index carried a hazard ratio of 1.26 (95 percent confidence interval, 0.89–1.79) and low muscle density 1.21 (0.86–1.71), neither statistically significant. Weight loss of ten percent or more yielded a hazard ratio of 1.56 (1.12–2.16, p = 0.008), while low handgrip strength dominated at 2.07 (1.47–2.92, p < 0.001). The pairwise combinations told the same story from another angle: patients with weak grips but preserved muscle index faced 2.53 times the mortality risk of the reference group, and low mass added little on its own. When strength, weight loss and muscle index were crossed into eight categories, only combinations including both weakness and weight loss reached significance, and the highest risk, a hazard ratio of 4.85 (2.88–8.15), fell to patients who were weak, had lost at least ten percent of their weight and also had low muscle mass. Low muscle density behaved identically when substituted for mass, and the models’ overall discrimination, captured by Harrell’s C-index, hovered near 0.78.

The biology behind these numbers may explain why function outpaces form. Impaired muscle function is multifactorial and likely reflects the inflammatory burden generated from the earliest stages of malignant disease, and it can manifest before substantial muscle catabolism becomes visible on a scan. Systemic inflammation degrades contractile machinery, shifts muscle fiber composition and blunts neural drive long before cross-sectional area shrinks past a diagnostic threshold. CT-based measures also carry two structural blind spots. A patient who begins treatment with a generous lifelong muscle reserve can lose a considerable amount of tissue yet remain within the population’s normal range, escaping detection entirely. Conversely, a naturally slight person with constitutional thinness may register as sarcopenic on every scan while retaining excellent functional capacity and performance status. Weight loss and grip strength sidestep both traps, registering relative change and actual output rather than a static anatomical snapshot. The pairing of weakness and wasting also aligns closely with the formal definition of cachexia and mirrors what has long been observed in chronic obstructive pulmonary disease, where inflammation, wasting and muscle dysfunction rather than body mass drive survival.

The practical implications are considerable. A hand dynamometer costs a fraction of a CT scan, requires minimal training and can be deployed in almost any clinic, while weight change is something patients themselves can observe and report between appointments. Both markers therefore allow early identification of at-risk patients who could benefit from tailored nutritional and exercise interventions, and both can be repeated cheaply throughout the disease course, whereas muscle imaging is tied to clinical scan schedules. The findings also resonate with interventional evidence. Randomized trials of anabolic agents in cancer cachexia have, disappointingly, improved body and muscle mass without meaningfully improving performance, muscle function or survival, suggesting that adding tissue is not the same as restoring capability. Meanwhile, multimodal prehabilitation combining exercise and nutrition before abdominal cancer surgery, and exercise-based programs before chemotherapy, have improved strength and performance while reducing postoperative complications, symptom burden and hospitalization rates and increasing tolerance of treatment. Geriatric sarcopenia research has shown for years that functional endpoints respond more robustly to intervention than body composition does, and the present study extends that logic into oncology.

The authors are candid about limitations. Standardized thresholds for muscle-related features, with the exception of percentage weight loss, remain contested; the team therefore repeated the analyses using quartiles of muscle area and density normalized for body weight and body mass index, as well as the widely used cutoffs proposed by Martin and colleagues, and obtained consistent results. Although the third lumbar vertebra is a validated predictor of whole-body skeletal muscle, the relationship between muscle loss and mortality could be muscle-dependent, and other compartments might perform differently. The case mix also leans heavily toward gastrointestinal cancer, a population in which weight loss is especially prevalent because systemic inflammation converges with nutrition-impact symptoms such as anorexia, dysphagia, nausea, early satiety and constipation. The sample size did not permit stratification by tumor type, leaving open whether grip strength predicts survival equally well in breast, lung or hematologic malignancies. Nor could the study pinpoint the underlying determinants of weight loss and weakness, since reduced food intake, inflammation and physical inactivity all contribute, although large meta-analyses confirm that systemic inflammation drives both weight loss and sarcopenia.

Even with those caveats, the conclusion lands with force. In this cohort, reduced muscle strength and clinically significant weight loss were stronger and more consistent predictors of death than muscle mass or composition measured on CT, reinforcing their status as the most accessible and most informative markers of muscle health in cancer care. The result effectively inverts the traditional hierarchy: rather than using expensive imaging to find atrophy and then wondering about function, clinicians may do better to start with function and weight and reserve imaging for selected questions. Future studies focused on individual tumor types, and on the mechanisms linking inflammation to weakness, will be needed to translate these markers into patient-tailored interventions. For now, the message to oncology is refreshingly simple and strikingly democratic: the two best prognostic tools for muscle health may be a dynamometer any clinic can afford and a scale every patient already owns.